EasyManua.ls Logo

Flashback Technologies M1 - Page 3

Default Icon
24 pages
Print Icon
To Next Page IconTo Next Page
To Next Page IconTo Next Page
To Previous Page IconTo Previous Page
To Previous Page IconTo Previous Page
Loading...
Page 3 of 24
M1 Compliance ........................................................................................................................................... 18
Nonin 8000AA Warranty ............................................................................................................................. 18
M1 Warranty ............................................................................................................................................... 18
M1 Data Sheet ............................................................................................................................................ 19
The Compensatory Reserve Index (CRI) ...................................................................................................... 19
Estimating CRI from Pulsatile Waveforms .............................................................................................. 20
Performance of CRI ................................................................................................................................. 20
Summary of Clinical Study .......................................................................................................................... 21
Background Information Regarding Use of CRI ...................................................................................... 21
Compensatory Reserve ....................................................................................................................... 21
Development of the Compensatory Reserve Index (CRI) ................................................................... 21
Clinical Validation of CRI ..................................................................................................................... 22
Conclusions ......................................................................................................................................... 24
Clinical Use Considerations ......................................................................................................................... 24
References .................................................................................................................................................. 24